12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Soluble Ferric Pyrophosphate: Completed Phase III enrollment

Rockwell Medical said it completed enrollment in the double-blind, placebo-controlled Phase III CRUISE-2 trial evaluating 11 µg/dL SFP delivered via dialysate 3-4 times per week for up to 18 months in about 300 patients. In May, Rockwell Medical completed...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >